In order to strengthen the company’s liquidity and to ensure the continued development of the company’s pipeline, on July 27, 2022 the Aqilion Board of Directors decided on to carry out an issue with priority for existing owners. The issue was carried out during the third quarter of 2022 as an issue of units, which brought the company approximately SEK 30.5 million before issue costs. Each unit contained four (4) shares and two (2) options of the subscription series TO1.

All warrants (100%) in warrant series TO1 have now been converted to shares, which has added SEK 20.1 million to the company. The number of shares in the company after the conversion of the warrants amounts to 6,860,166 shares and the share capital amounts to SEK 3,430,083.

“We thank our shareholders for their support. The capital injection will primarily be used for our early research projects with focus on new innovative treatments for chronic inflammatory diseases where there is a pronounced medical need, but only few or no treatments,” says Sarah Fredriksson, CEO of Aqilion.

For more information, please contact:
Sarah Fredriksson, CEO, AQILION AB, + 46 (0)70 261 4575, sarah.fredriksson@aqilion.com

About Aqilion

Aqilion is a biotech company that focuses on developing new innovative treatments for diseases caused by chronic inflammation and dysfunctional immune reactions such as autoimmune diseases. The company is mainly active in the early phases of drug discovery, from idea to early clinical development.

Aqilion combines its experience from major pharmaceutical companies with the drive and entrepreneurship of small growth companies. With solid experience in business development in innovative biotech and pharmaceutical companies, the company’s experienced team and Board of Directors have successfully navigated the process from drug discovery to market.

AQILION AB (publ) is a Swedish public limited company headquartered in Helsingborg, Sweden. www.aqilion.com